Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk
详细信息 查看全文
- 作者：Alina Anton (1)
Sarah Schott (2)
Gisela Kaip (1)
Michelle Rath (2)
J?rg Heil (2)
Sebastian Aulmann (1)
Hans-Peter Sinn (1) (3) - 关键词：Fallopian tube ; Fimbriae ; Ovarian carcinogenesis ; BRCA1 risk
- 刊名：Archives of Gynecology and Obstetrics
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：289
- 期：5
- 页码：1079-1085
- 全文大小：987 KB
- 参考文献：1. Waldmann A, Eisemann N, Katalinic A (2013) Epidemiology of malignant cervical, corpus uteri and ovarian tumours—current data and epidemiological trends (Epidemiologie der b?sartigen tumoren der inneren weiblichen genitalorgane—aktuelle zahlen und epidemiologische trends). Geburtsh Frauenheilk 73(02):123-29. doi:10.1055/s-0032-1328266
2. Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4(5):447-51
3. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4):385-94. doi:10.1016/S1470-2045(11)70404-1
4. Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57(6):1457-462
5. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15(1):103-05. doi:10.1038/ng0197-103
6. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365-372
7. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al (1998) Genetic heterogeneity and penetrance analysis of the / BRCA1 and / BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676-89 pii: S0002-9297(07)63848-8
8. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643-46. doi:10.1126/science.1088759
9. Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, Jacobs IJ, Menko FH, Kenemans P (2000) Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 76(1):45-0. doi:10.1006/gyno.1999.5623
10. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA (2001) Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80(2):176-80. doi:10.1006/gyno.2000.6071
11. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195(4):451-56. doi:10.1002/path.1000
12. Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, Narod SA (2001) A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 80(3):341-45. doi:10.1006/gyno.2000.6095
13. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609-615. doi:10.1056/NEJMoa020119
14. Rebbeck TR (2002) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 38(Suppl 6):S15–S17 (pii: S0959804902002691)
15. Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P (2003) Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95(14):1072-078
16. Herrington CS, McCluggage WG (2010) The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol 220(1):5-. doi:10.1002/path.2630
17. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100(1):58-4. doi:10.1016/j.ygyno.2005.06.065
18. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23(1):127-32. doi:10.1200/JCO.2005.04.109
19. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109(2):168-73. doi:10.1016/j.ygyno.2008.01.012
20. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP (2006) Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 13(1):1-. doi:10.1097/01.pap.0000201826.46978.e5
21. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30(2):230-36 (pii: 00000478-200602000-00012)
22. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B (2001) Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25(10):1283-289
23. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY (2005) BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 106(6):1327-334. doi:10.1097/01.AOG.0000187892.78392.3f
24. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih Ie M (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29(2):218-24 (pii: 00000478-200502000-00009)
25. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J (2004) Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 93(2):301-06. doi:10.1016/j.ygyno.2004.01.043
26. R Development Core Team (2011) R: a language and environment for statistical computing. Vienna
27. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31(2):161-69. doi:10.1097/01.pas.0000213335.40358.47 - 作者单位：Alina Anton (1)
Sarah Schott (2)
Gisela Kaip (1)
Michelle Rath (2)
J?rg Heil (2)
Sebastian Aulmann (1)
Hans-Peter Sinn (1) (3)
1. Department of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany
2. Department of Gynecology and Obstetrics, University Hospital Heidelberg, Vo?str. 9, 69115, Heidelberg, Germany
3. Sektion für Gyn?kologische Pathologie, Pathologisches Institut, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany - ISSN：1432-0711
文摘
Purpose The fallopian tube has been implicated as a site of origin of sporadic and BRCA1-related ovarian cancer. To investigate if Ki-67 or p53 is altered in BRCA1 mutation carriers, we have studied the expression of these markers in morphologically normal mucosa in the fallopian tube and fimbriae. Methods Prophylactic adnexectomy specimens from 24 patients (eight BRCA1 mutation carriers, eight non-mutation carriers, and eight with unknown BRCA1 status), were scored by automated image analysis for the amount of Ki-67 and wild-type p53 expression. All patients had a history of breast cancer and a family history of breast or ovarian cancer. Results In the fimbriae, a median of 0.42?% Ki-67 and 0.04?% p53-positive epithelial cells was present, compared to a median of 0.36?% for Ki-67 and 0.05?% for p53 in the fallopian tube. Ki-67 expression decreased significantly with age (r?=??.45, p?=?0.028). In contrast, p53 expression was not age-dependent for the whole group of patients (r?=?0.25, p?=?0.25). Subgroup analysis revealed a difference for p53 expression of the BRCA1 mutation carriers with respect to age (median 0.039 vs. 0.082?% for age less or greater than 50.5?years). Consequently, the p53/Ki-67 ratio showed an age-dependent increase, which was accelerated in the BRCA1-positive patients. Conclusions Ki-67 and p53 expression varies in morphologically normal tubal epithelial cells depending on age and BRCA1 mutation status. This may reflect an altered and age-dependent DNA repair in BRCA1 mutation carriers and may be related to increased risk of ovarian cancer arising in the fallopian tube.